You are here: Industry Insights > Y-Biologics

News List

Y-Biologics, Pierre Fabre Enter Immuno-oncology Alliance contractpharma
July 08, 2021
Aims to develop and commercialize a family of human antibodies to inhibit the growth of tumor cells.
South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology prnasia
July 06, 2021
The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated ...
Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory prnasia
January 05, 2021
The South Korean biotech company Y-Biologics and the China-based biopharmaceutical company 3D Medicines have entered into a License Agreement granting exclusive rights to develop, manufacture, and commercialize YBL-013 ...
Creation of a research partnership between Pierre Fabre and Y-Biologics for the development of new immunotherapies based on monoclonal antibodies prnasia
November 23, 2020
The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a strategic partnership in the field of immuno-oncology research.